41
There is a requirement for tumor cells to self-renew and proliferate in order to perpetuate 42 tumorigenesis. It is perhaps not surprising that tumor-initiating cells or cancer stem cells share 43 similar signal transduction processes with normal stem cells 1, 2 . The ability for self-renewal and 44 differentiation in both stem cells and cancer stem cells have converged on a common pathway 45 known as Wnt signaling 3, 4 . Wnt proteins are highly conserved across the animal kingdom, 46 functioning as developmentally important molecules controlling cell fate specification, cell 47 polarity and homeostatic self-renewal processes in embryonic and adult stem cells 5 . Wnts are 48 a group of glycoproteins serving as ligands for the frizzled receptor to initiate signaling 49 cascades in both canonical and non-canonical pathways 6 . Beyond embryogenesis, Wnt 50 proteins control cell fate determination in adults where they regulate homeostatic self-51 renewal of intestinal crypts and growth plates [7] [8] [9] . 52 53 Wnt signaling is the product of an evolutionary adaptation to growth control in multicellular 54 organisms, and it has now become clear that aberrations in this pathway contributes to 55 deranged cell growth associated with many disease pathologies including cancer 10 . Loss-of-56 function mutations in genes that inhibit the Wnt pathway lead to ligand-independent 57 constitutive activation of Wnt signaling in hepatocellular carcinoma 11 , colorectal cancer 12 , 58 gastric cancer 13 and acute myeloid leukemia 14 . Thus, inhibition of Wnt signaling would hold 59 great promise as therapeutic targets 15 . A small molecule inhibitor ICG-001 functions to inhibit 60 the degradation of the Wnt repressor Axin and treatment of colon cancer cell lines with this 61 inhibitor resulted in increased apoptosis 16 . Antibodies against Wnts and frizzled receptors have 62 also demonstrated antitumor effects 17, 18 . 63 and transcriptional dysregulation of Wnt pathway members. Activating mutations of β-catenin 66 have been implicated in adrenocortical tumorigenesis 19 and multiple gastrointestinal 67 cancers 20 . Downregulation of a Wnt antagonist DKK1, a downstream target of β-catenin, is also 68 observed in colorectal cancer 21 . However, there is limited understanding on the role of somatic 69 copy number alterations in Wnt pathway genes as well as their downstream targets on driving 70 tumor progression and patient prognosis. Studies examining the transcriptional dysregulation 71 of Wnt pathway genes offered limited insights into whether differences in transcript 72 abundance were caused by genomic amplifications or losses. 73
74
Given the complexity of Wnt signaling in cancer, it is important to investigate genomic 75 alterations alongside transcriptional regulation of all genes associated with Wnt signaling in a 76 comparative approach. We hypothesize that pan-cancer transcriptional aberrations in Wnt 77 signaling is caused by genomic amplifications of a group of genes known as Wnt drivers and 78 that transcriptional profiles of driver genes are important predictors of patient outcome. We 79 conducted a pan-cancer analysis on 147 Wnt signaling genes, which involved positive and 80 negative regulators of the pathway alongside their downstream targets. We analyzed 18,484 81 matched genomic and transcriptomic profiles representing 21 cancer types to determine 82 whether 1) somatic copy number amplifications are drivers of hyperactive Wnt signaling, 2) 83
Wnt driver genes harbor clinically relevant prognostic information and 3) crosstalk exists 84 between Wnt driver genes, tumor hypoxia and signaling pathways associated with stem cell 85
Pan-cancer prognostic relevance of the newly identified core Wnt drivers 213
214
We rationalize that the gain of function of the core Wnt drivers could influence patient 215 outcome. Univariate Cox proportional hazards regression analyses were performed on the 216 transcriptional profiles of each of the 16 Wnt drivers on 20 cancers where survival information 217 is available. A vast majority of the core Wnt driver genes were significantly associated with 218 poor prognosis (hazard ratio [HR] above 1, P<0.05) (Fig. S1 ). Interestingly, there were variations 219 in the number of prognostic genes between cancers. Esophageal cancer (ESCA) had no 220 prognostic genes and only two genes were prognostic in sarcoma (SARC) and 221 cholangiocarcinoma (CHOL). In contrast, clear cell renal cell carcinoma (KIRC) and the pan-222 kidney cohort (KIPAN) involving chromophobe renal cell, papillary renal cell and clear cell renal 223 cell carcinoma had 13 and 10 prognostic genes respectively (Fig. S1 ). To determine whether 224 core Wnt driver genes harbored prognostic information as a gene set, we calculated expression 225 scores for each patient in each cancer type by taking the mean expression of the 16 Wnt 226 drivers. Patients were subsequently median-dichotomized into low-and high-score groups for 227 survival analyses. Remarkably, when the core Wnt drivers were considered as a gene signature, 228
we observed that patients with high scores had significantly poorer survival rates in six cancer 229 cohorts (n=3,050): bladder (P=0.011), colon (P=0.013), head and neck (P=0.026), pan-kidney 230 (P<0.0001), clear cell renal cell (P<0.0001) and stomach (P=0.032) (Fig. 2) . 231
232
To determine whether the 16-Wnt-gene signature harbored independent prognostic value 233 over current tumor, node and metastasis (TNM) staging system, the signature was evaluated 234 (Fig. 4) . Importantly, when the signature was used as a 261 combined model with TNM staging, we observed a further increase in AUC suggesting that the 262 signature offered incremental predictive value: bladder (AUC=0.713), colon (AUC=0.723), head 263 and neck (AUC=0.663), pan-kidney (AUC=0.833), clear cell renal cell (AUC=0.818) and stomach 264 (AUC=0.757) (Fig. 4) suggesting that in these two cancers, hypoxic tumors had higher expression of core Wnt drivers 292 (Fig. 5A) . 293
294
To determine the clinical relevance of this positive association, we separated patients into four 295 groups: 1) high scores for both 16-gene and hypoxia, 2) high 16-gene score and low hypoxia 296 score, 3) low 16-gene score and high hypoxia score and 4) low scores for both 16-gene and 297 hypoxia (Fig. 5A ). Kaplan-Meier analyses were performed on the four patient groups and we 298 observed that the combined relation of Wnt hyperactivation and hypoxia was significantly 299 associated with overall survival in both cancers: bladder (P=0.009) and clear cell renal cell 300 (P<0.0001) (Fig. 5B) . Notably, patients with high hypoxia and high 16-gene scores had 301 significantly higher mortality rates compared to those with low hypoxia and low 16-gene 302 scores: bladder (HR=1.897, P=0.0096) and clear cell renal cell (HR=2.946, P<0.0001) (Fig. 5C (Fig. S2 ). Gene ontology (GO) enrichment analyses revealed 315 enrichment of biological processes consistent with those of cancer stem cells: cell proliferation, 316 cell differentiation, embryo development and cell morphogenesis (Fig. 6A) . Moreover, despite 317 their diverse tissue origins, high-score patients from all six cancers exhibited remarkably similar 318 biological alterations (Fig. 6A) (Table S4 ). For example, high-score patients appear to show a 319 phenotype associated with loss of cell adhesion properties. Genes involved in regulating cell 320 adhesion were downregulated and the 'cell adhesion' GO term was among the most enriched 321 ontologies across all six cancers (Fig. 6A) . As a further confirmation, differentially expressed 322 genes were mapped to the KEGG database and enrichments of ontology related to cell 323 adhesion molecules were similarly observed (Fig. 6B) (Fig. 6B, C) . Within the tumor microenvironment, collagen can modulate extracellular 329 matrix conformation that could paradoxically promote tumor progression 40, 41 . Indeed, we 330 observed the enrichment of numerous collagen-related Reactome pathways: assembly of 331 collagen fibrils, collagen biosynthesis, collagen formation, collagen chain trimerization andcollagen degradation (Fig. 6C) . Overall, our results suggest that elevated mortality risks in high-333 score patients could potentially be due to loss of cell adhesion and aggravated disease states 334 exacerbated by Wnt hyperactivation. 335
336
To determine the extent of the loss of adhesive properties in tumor cells expressing high levels 337
of Wnt driver genes, we examined the expression profiles of 32 genes from the major cadherin 338 superfamily. Major cadherins are a group of highly conserved proteins that encode at least five 339 cadherin repeats, which include type I and II classical cadherins (CDH1, CDH2, CDH3, CDH4, 340 CDH5, CDH6, CDH7, CDH8, CDH9, CDH10, CDH11, CDH12, CDH13, CDH15, CDH18, CDH19, 341 CDH20, CDH22, CDH24 and CDH26) 2) high 16-gene score and low EZH2 expression, 3) low 16-gene score and high EZH2 expression 374 and 4) low 16-gene score and low EZH2 expression (Fig. 7A) . Interestingly, patients with high 375 16-gene score that concurrently had high EZH2 expression had the poorest survival outcomes 376 compared to the others: pan-kidney (P<0.0001) and clear cell renal cell (P<0.0001) (Fig. 7B) . 377
This suggests that Wnt hyperactivation and EZH2 overexpression could synergize to drive 378 tumor progression resulting in significantly higher death risks: pan-kidney (HR=3.444, 379 P<0.0001) and clear cell renal cell (HR=3.633, P<0.0001) (Fig. 7C ).
Discussion and Conclusion 381 382
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